Anish Khan1*, Aishwarya Soni2 and Amit Kumar3
1Centre for Biotechnology, Maharshi Dayanand University, Rohtak-124001, Haryana, India
2Department of Biotechnology, Deenbandhu Chhotu Ram University of Science and Technology-Murthal, Sonepat-131039, Haryana, India
3Assistant Professor, Head of the Department of Zoology, Government College for Women, Gohana-131301, Sonepat, Haryana, India
*Corresponding Author: Anish Khan, Centre for Biotechnology, Maharshi Dayanand University, India. Email: firstname.lastname@example.org
Received: June 10, 2021; Published: July 01, 2021
Corona virus disease-2019 (COVID-19) is a pandemic entity caused by a novel corona virus (severe acute respiratory syndrome-coronavirus-2; SARS-CoV-2), which was firstly reported in Wuhan, Hubei territory in China on December 2019 [1,2]. SARS-CoV-2 is continuing to spread worldwide to till date with a high proportion of infected or affecting ≥10 million individuals globally . Until now, there is no permanent cure for pandemic COVID-19 disease, though a variety of executive options have been evaluated and managed with systemic glucocorticoids for recovery of endurance rate of COVID-19 patients . However, an array of complications reported during and post COVID-19 infection due to extensive use of glucocorticoids, which may lead to secondary fungal co-infection [1,2].
Citation: Anish Khan., et al. “Mucormycosis: Current Update in Pandemic COVID-19". Acta Scientific Microbiology 4.8 (2021): 01-02.
Copyright: © 2021 Anish Khan., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.